Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) have earned a consensus rating of “Moderate Buy” from the five brokerages that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $41.00.

ELVN has been the subject of several research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Wednesday, January 21st. Wall Street Zen raised shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th.

Insider Activity

In other news, COO Anish Patel sold 48,300 shares of the company’s stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $27.99, for a total transaction of $1,351,917.00. Following the completion of the transaction, the chief operating officer directly owned 215,011 shares of the company’s stock, valued at $6,018,157.89. This represents a 18.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Joseph P. Lyssikatos sold 20,000 shares of the stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $26.75, for a total value of $535,000.00. Following the transaction, the insider owned 745,188 shares of the company’s stock, valued at approximately $19,933,779. The trade was a 2.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 259,280 shares of company stock worth $6,635,968 over the last three months. Corporate insiders own 25.90% of the company’s stock.

Institutional Trading of Enliven Therapeutics

A number of institutional investors have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Enliven Therapeutics by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock worth $44,000 after purchasing an additional 594 shares during the last quarter. Invesco Ltd. lifted its position in Enliven Therapeutics by 4.3% during the 2nd quarter. Invesco Ltd. now owns 21,957 shares of the company’s stock worth $440,000 after buying an additional 913 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Enliven Therapeutics by 33.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after buying an additional 930 shares during the last quarter. Quantbot Technologies LP grew its holdings in shares of Enliven Therapeutics by 47.1% in the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after acquiring an additional 1,434 shares in the last quarter. Finally, Legal & General Group Plc grew its holdings in shares of Enliven Therapeutics by 4.8% in the 3rd quarter. Legal & General Group Plc now owns 33,765 shares of the company’s stock valued at $691,000 after acquiring an additional 1,540 shares in the last quarter. Institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Trading Up 0.3%

NASDAQ:ELVN opened at $25.87 on Tuesday. Enliven Therapeutics has a 1 year low of $13.30 and a 1 year high of $29.98. The stock has a 50-day moving average price of $20.52 and a two-hundred day moving average price of $20.38. The stock has a market cap of $1.54 billion, a price-to-earnings ratio of -14.06 and a beta of 0.41.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.11. Sell-side analysts forecast that Enliven Therapeutics will post -1.95 earnings per share for the current year.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.